Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Chem Biol Interact ; 291: 111-119, 2018 Aug 01.
Article in English | MEDLINE | ID: mdl-29883724

ABSTRACT

Alisol A 24-acetate (AA), a natural triterpenoid isolated from the traditional Chinese medicine Rhizoma Alismatis, has various therapeutic effects. We investigated the anti-nonalcoholic steatohepatitis (NASH) effect of AA and its underlying mechanisms in vitro and in vivo. C57BL/6 mice were fed a methionine and choline-deficient (MCD) diet for 4 weeks to induce NASH. The mice were simultaneously treated with a daily dose of AA (15, 30, and 60 mg kg-1, ig) for 4 weeks. On the last day, the animals were sacrificed and plasma and liver tissue were collected. Serum and liver tissue biochemical analyses and histological observation were performed. The human hepatic stellate cell line LX-2 was used to build NASH models by culturing with conditioned medium from WRL-68 liver cells after exposure to MCD medium in vitro. Liver oxidative stress and inflammatory indices and autophagy markers were examined. The results showed that AA suppressed reactive oxygen species (ROS) and inflammation in a NASH mouse model and inhibited the expression of inflammatory cytokines and ROS in LX-2 cells in MCD medium. Furthermore, we found AA stimulated autophagy in mice liver and LX-2, which could be the underlying mechanism of AA in NASH. To further investigate the role of autophagy in LX-2 cells, we found that AA regulated autophagy via the AMPK/mTOR/ULK1 pathway and dorsomorphin, a selective AMPK inhibitor, led to the suppression of AA-induced autophagy. Taken together, our results indicate that AA could be a possible therapy for NASH by inhibiting oxidative stress and stimulating autophagy.


Subject(s)
Adenylate Kinase/metabolism , Autophagy , Cholestenones/therapeutic use , Non-alcoholic Fatty Liver Disease/drug therapy , Non-alcoholic Fatty Liver Disease/pathology , Oxidative Stress , Signal Transduction , TOR Serine-Threonine Kinases/metabolism , Animals , Autophagy/drug effects , Cell Line , Cholestenones/chemistry , Cholestenones/pharmacology , Choline , Diet , Disease Models, Animal , Humans , Liver/drug effects , Liver/pathology , Male , Methionine/deficiency , Mice, Inbred C57BL , Non-alcoholic Fatty Liver Disease/enzymology , Oxidative Stress/drug effects , Signal Transduction/drug effects
2.
Drug Des Devel Ther ; 10: 2021-8, 2016.
Article in English | MEDLINE | ID: mdl-27382255

ABSTRACT

The aim of the present study was to design a new pH-enzyme double-dependent mesalamine colon-specific delivery system. The drug release behaviors in vitro and pharmacokinetics and biodistribution in vivo were further evaluated. The mean particle diameters of mesalamine-coated microparticles were 312.2 µm. In vitro, a small amount of mesalamine was released in HCl at a pH of 1.2 and PBS medium at a pH of 7.4 for 5 hours, and 71% of the entrapped mesalamine was further released during the subsequent 20 hours of incubation. A greater area under the plasma concentration-time curve (AUC)0-t was obtained for the coated microparticles (1.9-fold) compared to the suspensions group, which indicated that the encapsulated mesalamine had mostly been absorbed in rats over the period of 12 hours. The AUC0-t of the coated microparticles in colon was 2.63-fold higher compared to the suspensions (P<0.05). Hence, mesalamine-coated microparticles are considered to maintain the drug concentration within target ranges for a long period of time.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Colon/metabolism , Drug Delivery Systems/methods , Mesalamine/administration & dosage , Mesalamine/pharmacokinetics , Animals , Drug Liberation , Female , Hydrogen-Ion Concentration , Male , Mice , Particle Size , Rats , Rats, Sprague-Dawley , Surface Properties , Tissue Distribution
3.
Drug Deliv ; 23(3): 992-8, 2016.
Article in English | MEDLINE | ID: mdl-24937382

ABSTRACT

The aim of this study was to prepare levofloxacin-loaded chitosan microspheres and to evaluate their in vitro and in vivo characteristics. Glutaraldehyde-crosslinked microspheres were prepared using a spray-drying method, and characterized in terms of the morphological examination, particle size distribution, entrapment efficiency, drug loading and in vitro release. Pharmacokinetics and colon biodistribution studies were used to evaluate that microspheres have more advantage than the conventional formulations. The surface morphology of the freeze-dried microspheres were smooth, discrete with a regular spherical to near-spherical shape. Size of the microspheres after freeze-drying was 4.96 ± 0.76 µm and well-distributed. The zeta potential of microspheres was -29.3 ± 2.1 mV. An average drug loading of 9.3 ± 0.4% and encapsulation efficiency of 81.1 ± 4.7% of levofloxacin microspheres were obtained with the optimized preparation parameters. The cumulative release rate of levofloxacin microspheres was followed by a sustained release and fitted for classic Higuchi kinetic model. In vivo studies showed that chitosan microspheres are thought to have the potential to maintain levofloxacin concentration within target ranges for a long time, decreasing side effects caused by concentration fluctuation, ensuring the efficiency of treatment and improving patient compliance by reducing dosing frequency. It also does not cause any harmful or toxic effect in colon and rectum as evaluated by histopathologic studies.


Subject(s)
Colon/drug effects , Levofloxacin/administration & dosage , Levofloxacin/chemistry , Administration, Oral , Animals , Chemistry, Pharmaceutical/methods , Chitosan/chemistry , Colon/metabolism , Drug Delivery Systems/methods , Freeze Drying/methods , Glutaral/chemistry , Levofloxacin/pharmacokinetics , Microspheres , Particle Size , Rats , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...